Clinical trials: Intravenous
Ulcerative Colitis
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.
- Trial name
- NCT00694980
- Testing
- rhuMAb Beta7
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 48 people
- Sponsor
- Genentech, Inc.
Healthy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single-ascending IV doses of FB825
- Trial name
- NCT02309762
- Testing
- FB825
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Fountain Biopharma Inc.
Sarcoma, Soft Tissue
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied.
- Trial name
- NCT02326025
- Testing
- Olaratumab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Epilepsies, Partial
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures
Subjects enrolled in the SP615, SP756, or SP774 open-label extension (OLE) trials receiving oral SPM 927 for at least 8 weeks and a stable dose of up to 3 antiepileptic medications may participate in a research trial at…
- Trial name
- NCT00151879
- Testing
- SPM 927
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UCB Pharma
Abuse, Drug
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
A double-blind, randomized crossover study to assess the subjective abuse potential of intravenous remimazolam compared to midazolam and placebo in recreational CNS depressant users
- Trial name
- NCT04110535
- Testing
- Remimazolam, Midazolam, Saline
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Paion UK Ltd.
Anemia
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
This study will assess the efficacy and safety of methoxy polyethylene glycol-epoetin beta (Mircera) in the maintenance of hemoglobin levels in patients who have previously received treatment with epoetin alfa or darbepoetin…
- Trial name
- NCT00454246
- Testing
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Where
- 78 sites in United States
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
To evaluate the incidence of the outcomes for the safety specifications in patients of Medical Data Vision database in Japan diagnosed with CD20 positive B-cell non- Hodgkin's lymphoma who were treated with Rituximab Pfizer to…
- Trial name
- NCT06790420
- Testing
- Rituximab Pfizer, Rituxan
- Where
- Japan
- Volunteers
- 2,703 people
- Sponsor
- Pfizer
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab
Squamous Cell Carcinoma of Head and Neck
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed…
- Trial name
- NCT04633278
- Testing
- CMP-001, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteers
A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body
To investigate rates and routes of excretion, mass balance, pharmacokinetics of parent drug, any known metabolites, and total radioactivity, metabolite profiling, metabolite identification, if suitable assays are available…
- Trial name
- NCT04267276
- Testing
- Part 1: BI 1265162 - intravenous, Part 2: BI 1265162 - oral
- Where
- Netherlands
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Psoriasis Vulgaris
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
The purpose of this protocol is to determine the single-dose pharmacokinetics and immunogicity of BMS-188667 administered as a 1 hour intravenous infusion with extended pharmacokinetic sampling.
- Trial name
- NCT00277225
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bristol-Myers Squibb
Brain Contusion
A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion
The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional…
- Trial name
- ASTRAL (NCT03954041)
- Testing
- BIIB093
- Where
- 63 sites in United States, France and 5 more
- Volunteers
- 92 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Atopic Dermatitis
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT01732510
- Testing
- MK-8226
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Advanced Solid Tumors
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in participants with advanced solid tumors which are not amenable to standard treatment.
- Trial name
- NCT01494688
- Testing
- Paclitaxel, RO5509554
- Where
- 7 sites in United States, France
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara…
- Trial name
- NCT03277105
- Testing
- Dara SC, Dara IV
- Where
- 146 sites in United States, Australia and 16 more
- Volunteers
- 522 people
- Sponsor
- Janssen Research & Development, LLC
POI
Safety and Efficacy of YB-1113 in Treatment of POI
This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).
- Trial name
- NCT05494723
- Testing
- YB-1113
- Volunteers
- 6 people
- Sponsor
- Bright Cell, Inc.
Infections, Bacterial
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830
A phase I, first-time-in-human (FTIH), randomized, double-blind, placebo controlled, dose-escalation study is conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of GSK3342830 after administration of…
- Trial name
- NCT02751424
- Testing
- GSK3342830
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP)
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.
- Conditions
- Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
- Trial name
- NCT00157079
- Testing
- Immune Globulin Intravenous (Human), 10%
- Where
- 11 sites in United States
- Volunteers
- 61 people
- Sponsor
- Baxalta now part of Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.